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Abstract
Background: The small airway epithelium (SAE), the cell population that covers the human airway surface from
the 6
th generation of airway branching to the alveoli, is the major site of lung disease caused by smoking. The
focus of this study is to provide quantitative assessment of the SAE transcriptome in the resting state and in
response to chronic cigarette smoking using massive parallel mRNA sequencing (RNA-Seq).
Results: The data demonstrate that 48% of SAE expressed genes are ubiquitous, shared with many tissues, with
52% enriched in this cell population. The most highly expressed gene, SCGB1A1, is characteristic of Clara cells,
t h ec e l lt y p eu n i q u et ot h eh u m a nS A E .A m o n go t h e rg e n es expressed by the SAE are those related to Clara
cell differentiation, secretory mucosal defense, and mucociliary differentiation. The high sensitivity of RNA-Seq
permitted quantification of gene expression related to infrequent cell populations such as neuroendocrine cells
and epithelial stem/progenitor cells. Quantification of the absolute smoking-induced changes in SAE gene
expression revealed that, compared to ubiquitous genes, more SAE-enriched genes responded to smoking with
up-regulation, and those with the highest basal expression levels showed most dramatic changes. Smoking had
no effect on SAE gene splicing, but was associated with a shift in molecular pattern from Clara cell-associated
towards the mucus-secreting cell differentiation pathway with multiple features of cancer-associated molecular
phenotype.
Conclusions: These observations provide insights into the unique biology of human SAE by providing quantit-
ative assessment of the global transcriptome under physiological conditions and in response to the stress of
chronic cigarette smoking.
Background
The tracheobronchial tree, a dichotomous branching
structure that begins at the larynx and ends after 23
branches at the alveoli, is lined by an epithelium com-
prised of 4 major cell types, including ciliated, secretory,
undifferentiated columnar and basal cells [1,2]. The air-
way epithelium is exposed directly to environmental
xenobiotics, particulates, pathogens and other toxic sub-
stances suspended in inhaled air [2-4]. Of these, chronic
cigarette smoking, with its 4000 xenobiotics and > 10
14
oxidants per puff, is a major cause of airway disease,
including chronic obstructive pulmonary disease
(COPD) and bronchogenic carcinoma [4-6]. It is the air-
way epithelium that exhibits the first abnormalities rele-
vant to COPD and lung cancer, and it is the small
airway epithelium (SAE; ≥ 6
th generation) that is the pri-
mary site of the early manifestations of the majority of
smoking-induced lung disease [7]. As compared to prox-
imal airways, the small airway epithelium has unique
morphologic features with a decrease in the frequency
of basal cells and mucus-secreting cells accompanied by
increased numbers of Clara cells, a secretory cell sub-
type critical for the maintenance of the structural and
functional integrity at the airway-alveoli interface
[1,8-10].
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several studies using gene expression microarrays to
assess the transcriptome of the human airway epithe-
lium, demonstrating that smoking modulates the expres-
sion of hundreds of genes. The advent of RNA-Seq
technology, in which the entire polyadenylated tran-
scriptome is sequenced [19-24], is capable of building
on this microarray data to provide additional insights
into the transcriptome of the airway epithelium and its
response to cigarette smoke. Because RNA-Seq provides
direct sequencing information of all polyadenylated
mRNAs and is not limited by probe design, RNA-Seq
data has inherently less noise and higher specificity, and,
importantly, provides quantitative information on
mRNA transcript number [19]. With high sensitivity
and low background, RNA-Seq has a dynamic range of
> 8,000-fold, is highly reproducible, yields digital infor-
mation not requiring normalization, and can distinguish
individual members of highly homologous gene families
[25]. In the context of this background, the focus of this
study is to utilize massive parallel sequencing to quan-
tify the complete transcriptome of the human SAE in
healthy nonsmokers and healthy smokers.
Results
Study Population and SAE sampling
SAE samples from 5 healthy nonsmokers and 6 healthy
smokers were analyzed using mRNA-Seq (Additional
file 1, Table S1). All individuals had no significant prior
medical history and a normal physical examination. To
minimize the influence of potential confounding vari-
ables, only males of African-American ancestry were
assessed. The nonsmokers were younger (p < 0.02).
There were no differences be-tween the two groups
with respect to pulmonary function criteria (p > 0.1, all
variables). The smoking status was confirmed by urinary
tobacco metabolites (see Additional Data Methods and
Additional file 1, Table S1). The number of cells recov-
ered ranged from 5.0 to 9.7 × 10
6, with > 97% epithelial
cells in all cases (Additional file 1, Table S1). There was
no difference between the two groups with respect to
the proportions of each of the four major cell types,
with the exception of ciliated cells, which were signifi-
cantly lower in the healthy smokers compared to the
healthy nonsmokers (p < 0.04).
Data Processing and Quality Control
The cDNA generated from SAE samples was run in a
single lane per subject on Illumina flow cells. A total of
182 million, 43 base pair single end reads were gener-
ated, yielding 7.8 gigabases of sequence. These
sequences were aligned using Bowtie version 0.12 (see
Additional file 1, Table S2 for a summary of mapping
details). To correct for transcript length and depth of
coverage, raw reads were converted into reads per kilo-
base of exon per million mapped reads (RPKM) [23].
RPKM was then assessed across the entirety of reads
with reference to exons, introns and intergenic regions.
A comparison was made between the expression levels
of exons and intergenic regions to define a threshold
v a l u ea b o v ew h i c ht h e r ew a sthe highest confidence in
t h ev a l i d i t yo ft h ee x p r e s s i o nv a l u e( F i g u r e1 A ,B ) .T h i s
was performed by generating a false discovery rate for a
range of expression values across all subjects, resulting
in the adoption of a cut-off value of 0.125 RPKM, repre-
senting an optimal compromise between false positive
and false negative values (see Methods). All subsequent
analyses were based on the application of this expression
threshold.
Of the 21,475 annotated genes in the Human Genome
version 19 reference [26], 15,877 (73.9%) were expressed
in SAE at greater than the RPKM cut-off value of 0.125.
The average expression level was 13.8 RPKM (Figure
1C) and the average among subject coefficient of varia-
tion in RKPM was 0.25. This cut off may be conserva-
tive due to overestimation of the number of intronic
and intergenic reads. Based on a survey of a random
intergenic domain on the genome, we estimate that
~50% of the reads mapped to intergenic and intronic
regions correspond to repetitive elements. These prob-
ably represent mismapping of reads that properly belong
polyadenylated mRNAs that contain the same repetitive
elements. If the impact was to drop the threshold from
0.125, as used here, to 0.05, the number of expressed
genes would increase from 15,877 to 16,844 (a 6.1%
increase). It is estimated that 1 RPKM corresponds to
one mRNA per cell. As a result, we believe there is little
significant biology lost by using a conservative cut off
(consistent with literature precedent) of 0.125 (i.e., one
mRNA per 8 cells) vs am o r es t r i n g e n tc u to f fo f0 . 0 5
(one mRNA per 20 cells).
A subset of 12 genes with RPKM differing by > 4 logs
was confirmed by TaqMan realtime quantitative PCR
with relative quantitation, using rRNA for normaliza-
tion. The overall correlation between expression levels
determined by these 2 methods was very strong (r
2 =
0.81) (Additional file 1, Figure S1).
Comparison of SAE Gene Expression to Other Tissue
Transcriptomes
RNA-Seq allows absolute quantitation of mRNA levels
and for the fractional contribution of individual tran-
scripts to the total mRNA population to be assessed
[24]. In some tissues, transcripts from a relatively small
number of genes account for much of the total cellular
poly(A)
+ RNA pool (Figure 2A). In the case of liver, the
single most highly expressed gene contributes 10% of
the total mRNA molecules and the top ten collectively
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Figure 1 Establishment of detection limit for gene expression for RNA-Seq assessment of gene expression of the small airway
epithelium of healthy nonsmokers. A. Distribution of RPKM for exons (blue), introns (red), and intergenic regions (green). RPKM depends on
the size and read numbers mapped in the region considered. The RPKM for introns and intergenic regions was calculated by selecting intronic
and intergenic regions throughout the genome that match the size of the exons analyzed, i.e., the size is comparable for the introns, intergenic
regions, and exons. B. Estimate of minimum detectable level of expression (RPKM = 0.125) determined from an estimate of false discovery rate
(red) and false negative rate (purple) [24]. C. Average RPKM expression levels (log10). Dashed line represents the 0.125 threshold.
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Figure 2 Composition of the healthy nonsmoker small airway epithelium (SAE) transcriptome. A. Comparison of the SAE transcriptome to
that of other tissues. Abscissa - the number of genes, with the genes in descending order of mRNA level. Ordinate - fraction of all mRNAs
derived from these genes. The genes expressed by the small airway epithelium (blue) are compared to genes expressed by other organs as
indicated [24]. Note that the SAE is similar to liver in that a few genes are expressed at very high levels. B. RNA-Seq sequence alignments for
SCGB1A1 (uteroglobin; CC10), the most highly expressed gene in the SAE. The region of the genome corresponding to SCGB1A1 is shown with
the read coverage depth for 5 healthy nonsmokers plotted using Partek Genomics Suite version 6.5. RPKM for whole mRNA for each subject is
shown on the left. C-E. Frequency distribution of expression level for ubiquitous vs SAE-enriched genes in the small airway epithelium of healthy
nonsmokers. “Ubiquitous” genes are those expressed by most tissues; “SAE-enriched” genes are those more abundant in SAE compared to other
tissues (see text). For all panels, the number of genes in 1/2 log10 bins was determined starting at the detection limit (RPKM = 0.125). For each
panel, the expressed genes are grouped (in 1/2 log10 bins); low (-0.9 to 1), median (> 1 to 10) and high (> 10), with the number of genes and %
in each category listed and median RPKM for n = 5 healthy nonsmokers. C. All genes. D. Ubiquitous genes, representing 48% of all expressed
genes. E. SAE-enriched genes representing 52% of all expressed genes. Note that the SAE-enriched genes have a much larger proportion of low
level expressed genes compared to the ubiquitous genes. F, G. Comparison of coverage of RNA-Seq and microarray assessment of SAE gene
expression of healthy nonsmokers. Genes assessed by RNA-Seq were divided into low (0.125-1), median (> 1-10) and high (> 10) RPKM on the
basis of median expression level in n = 5 nonsmokers. Affymetrix U133 data for small airway epithelium for n = 27 African-American healthy
nonsmokers [[129]; Additional file 1, Table S1] were assessed based on the Affymetrix P calls in low expression (Affymetrix “present (P)” in < 50%;
red) or high expression in microarray ("P” in > 50%; blue). Genes with no unique probe on the microarray are identified in green. F. Ubiquitous
genes. G. SAE- enriched genes. For medium and high expressing genes the microarray and RNA-Seq are very similar in detecting expressed
genes, but for the SAE-enriched, low level expressed genes detected by RNA-Seq, the microarrays miss a large proportion of the genes.
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Page 4 of 31contribute 37% [24]. In colon, by contrast, the single top
mRNA contributes only 2% of the total mRNA and the
top ten contribute 9%[24]. Of the total SAE transcripts
identified in healthy nonsmokers, 13% mapped to the
SCGB1A1 gene (secretoglobin, family 1A, member 1
protein also known as ute-roglobin or Clara cell-specific
10 kD protein [CC10], Table 1). The top 10 genes con-
tributed 24% of the total mRNA (p < 0.05 comparing
distribution to both liver, and colon).
Ubiquitous and SAE-enriched Genes
To categorize the SAE-expressed genes in healthy non-
smokers as ubiquitous (i.e., expressed by most other tis-
sues) or genes expressed in an SAE-enriched fashion, a
comparison was made between the 7,897 genes identi-
fied by Ramsköld et al [24] to be ubiquitously expressed
in various human tissues and the 15,877 genes expressed
in human SAE. The data showed that 7,607 (96.5%) of
the genes identified by Ramsköld et al [24] as ubiqui-
tously expressed genes were also expressed by human
SAE, indicating that 48% of the SAE transcriptome is
comprised of ubiquitously expressed genes. The remain-
ing 52% were designated as “SAE-enriched” genes.
T h em o s th i g h l ye x p r e s s e dS A E - e n r i c h e dg e n e( T a b l e
1) was SCGB1A1, which is expressed primarily by
Clara cells located in small airways [27-29]. RNA-Seq
fragments mapped to all three exons of the SCGB1A1
gene at very high density (Figure 2B). Other highly
expressed SAE-enriched genes included secretoglobin,
family 3A, member 1(SCGB3A1), secretory leukocyte
peptidase inhibitor (SLPI), chromosome 20 open read-
ing frame 114 (C20orf114; also known as a long var-
iant of the palate, lung, and nasal epithelium
carcinoma associated protein PLUNC), tubulin poly-
merization-promoting protein family member 3
(TPPP3) and CD74.
Table 1 Overall Most Highly Expressed Genes in the SAE of Healthy Nonsmokers
1
Gene symbol Gene title Expression level in SAE (RPKM)
2
SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) 38675
SCGB3A1 secretoglobin, family 3A, member 1 7838
SLPI secretory leukocyte peptidase inhibitor 1602
C20orf114 chromosome 20 open reading frame 114 1484
TPPP3 tubulin polymerization-promoting protein family member 3 1302
CD74 CD74 molecule, major histocompatibility complex, class II invariant chain 947
TMEM190 transmembrane protein 190 945
GSTP1 glutathione S-transferase pi 1 859
WFDC2 WAP four-disulfide core domain 2 840
C20orf85 chromosome 20 open reading frame 85 738
TSPAN1 tetraspanin 1 664
C9orf24 chromosome 9 open reading frame 24 629
NEAT1 nuclear paraspeckle assembly transcript 1 (non-protein coding) 565
S100A11 S100 calcium binding protein A11 540
KRT19 keratin 19 493
MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) 461
ODF3B outer dense fiber of sperm tails 3B 392
CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 374
FOXJ1 forkhead box J1 363
LCN2 lipocalin 2 359
PIGR polymeric immunoglobulin receptor 351
MS4A8B membrane-spanning 4-domains, subfamily A, member 8B 348
ALDH3B1 aldehyde dehydrogenase 3 family, member B1 342
MSMB microseminoprotein, beta- 333
RSPH1 radial spoke head 1 homolog (Chlamydomonas) 318
CLDN4 claudin 4 308
AQP3 aquaporin 3 (Gill blood group) 308
C9orf117 chromosome 9 open reading frame 117 302
IGFBP2 insulin-like growth factor binding protein 2, 36 kDa 297
ANXA2P2 annexin A2 pseudogene 2 292
1 Listed are the top 30 most highly expressed SAE enriched genes.
2 Median for n = 5 healthy nonsmokers. PARTEK implementation of Bowtie algorithm with parameters as described in Material and Methods.
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Page 5 of 31To further characterize the SAE transcriptome, gene
expression levels derived from RNA-Seq data were
divided into three groups. “Low” expression was
assigned as significantly expressed (i.e., > 0.125 RPKM
cut off, but less than 1 RPKM, corresponding to < 1
mRNA/cell [23]). “Medium” expression was defined at
between 1 and 10 RPKM and “high” expression was
defined as > 10 RPKM (Figure 2C-E). Analyses of the
frequency distribution of ubiquitous and SAE-enriched
RefSeq-annotated genes revealed that considerably more
of the SAE-enriched gene set were expressed at lower
levels (median expression level 1.8 RPKM, Figure 2E)
compared to the ubiquitous genes (median expression
level 8.6 RPKM, Figure 2D).
Prior to the advent of RNA-Seq method, information
about the transcriptome of airway epithelium was
derived from gene expression microarrays [11-18]. To
assess the concordance of expression pattern by RNA-
Seq and microarrays, all genes expressed by RNA-Seq
were evaluated as to whether they were identified as
expressed in all microarrays, a subset of microarrays or
not represented on the microarray (Figures 2F, G). For
ubiquitous genes, the percentage of genes identified by
RNA-Seq also identified as expressed in > 50% of sub-
jects by microarray was greater for highly expressed
genes (97.7%) than medium expressed genes (92.1%).
Only 59.2% of ubiquitous genes with low expression
identified by RNA-Seq were scored as expressed by
microarray (Figure 2F). Similarly, for the SAE-enriched
genes, the percent of genes identified by RNA-Seq and
in > 50% of subjects by microarray was greater for
highly expressed genes (89.8%), compared to medium
expressed genes (70.3%), and even more so for genes
with low expression (31.3%; Figure 2G). Thus, overall,
the two methods are broadly in agreement, but RNA-
Seq provides more information, not only quantitative
data, but also identification of expression of genes with
low expression levels.
Functional Assessment of Ubiquitous and SAE-enriched
Genes
To better understand biologic functions enriched in the
SAE transcriptome, the gene lists were assigned to func-
tional categories using Gene Ontology molecular func-
tions and the expression levels for ubiquitous and SAE-
enriched genes were compared (Figure 3, Additional file
1, Table S3). In some functional categories such as sig-
nal transduction, the allotment of genes to the SAE-
enriched and ubiquitous categories, as well as the distri-
bution of expression levels within those categories, was
similar to that for all genes (compare Figure 3D to Fig-
ures 2D, E). But several deviations from the expected
distribution were observed. F o re x a m p l e ,f o rt h ef u n c -
tional category “translation”, many more genes were
classified as ubiquitous compared to SAE-enriched and
t h o s et h a tw e r eS A E - e n r i c h e d were expressed at higher
levels than expected based on all genes. By contrast, in
the category “immunity”, the number of genes in the
SAE-enriched category was higher than expected but
distribution of expression level was in line with the aver-
age expression of all genes. The median expression
levels among the various categories allowed quantifica-
tion of these differences. The median expression levels
for the SAE-enriched genes were lower than that for the
ubiquitous genes in all categories. For example, for the
ubiquitous genes, the median levels ranged from 7.9
RPKM for membrane receptors to 21.7 RPKM for trans-
lation, whereas, for the SAE-enriched genes, the median
levels ranged from 1.1 for membrane receptors to 5.6
RPKM for translation. On the average, the most highly
expressed category was “translation, ubiquitous” genes
(median 21.7 RPKM), whereas the lowest was “mem-
brane receptors, SAE-enriched” (median 1.1 RPKM).
The human SAE is made up of 4 major cell types
including ciliated cells (73% abundance in this study),
undifferentiated columnar cells (9%), basal cells (10%)
and secretory cells (7%, Additional file 2, Table S1). The
SAE also has rare neuroendocrine cells (< 0.01%)
[13,30,31]. The availability of cell type-specific gene lists,
together with the ability of RNA-Seq to quantify mRNA
abundance, allows the contributions of these cell types
to the SAE transcriptome to be assessed quantitatively.
When compared to all genes of the SAE-enriched tran-
scriptome, genes encoding cilia components were
expressed at much higher levels and genes encoding
neuroendocrine cell genes were expressed at much
lower levels (Figure 4). On the other hand, genes identi-
fied as representative of the basal cells and secretory
cells were expressed at levels comparable with the aver-
age level for SAE-enriched genes. The highest expressed
cilia-related genes included tubulin b2C and a1A subu-
nits, tektin and a number of dynein subunits with
RPKM of > 100 (Table 2). By contrast, neuroendocrine
genes such as secreogranin II (SCG2) and chromogranin
A (CHGA) were expressed at < 1 RPKM with the excep-
tion of enolase 2, which may not be neuroendocrine
cell-specific [32]. Among the mucus-secreting cell genes,
trefoil factor 3 and two mucin genes, MUC1 and
MUC5B, were the most highly expressed (RPKM > 100).
For the basal cell genes, when assessed in the context of
all SAE genes, MALAT1 (a noncoding transcript), CST3
cystatin C (a protease inhibitor) and PFN1 profilin 1 (a
ubiquitous actin monomer-binding protein) were the
most highly expressed.
To obtain insight into transcriptional regulation of the
SAE of nonsmokers, the SAE-enriched transcriptome
was surveyed for the most highly expressed transcription
factors in various structural categories (Table 3). Among
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Page 6 of 31the top 30 most highly expressed, the helix-turn-helix
dominated, with the basic helix-loop-helix and b-scaf-
fold categories next. Interestingly, the top 5 most highly
expressed SAE-enriched transcription factors all have
previously been established as having a role in airway
biology and/or lung cancer, including FOXJ1, ELF3,
TRIM29, SOX2, and FOXA1 [33-43]. RNA-Seq analysis
also revealed high expression levels for a variety of path-
way-specific transcription factors, including two (HES6,
HEY1) related to notch signaling.
To quantify the expression of the receptors and ligands
that may be involved in epithelial maintenance, the most
highly expressed transmembrane receptors in different
structural categories were identified (Table 4). Discoidin
domain receptor tyrosine kinase 1 (DDR1), a collagen
receptor associated with poor prognosis in non-small cell
lung cancer, was the most highly expressed transmem-
brane receptor [44]. There were a significant number of G
protein coupled, 7 transmembrane receptors in the highly
expressed category, including a homophilic cadherin-
coupled receptor (CELSR1) and the complement 5a recep-
tors, as well as 2 orphan receptors (GPR110, GPRC5C). In
addition to DDR1, there were also a number of highly
expressed tyrosine kinase receptors among the top 30,
including fibroblast growth factor receptors (FGFR3,
FGFR2) and the insulin like growth factor 1 receptor
(IGF1R). Interestingly, the receptors for oxytocin and
natriuretic peptide were also expressed at a high level.
With respect to ligands and growth factors, the most
highly expressed included multiple chemokines MDK,
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Page 7 of 31CXCL1, CX3CL1 and CXCL6 (Table 5). No known
ligand of the top 10 most highly expressed receptors
was expressed at RPKM > 5 in the SAE-enriched tran-
scriptome, nor was any known receptor for the top 10
highly expressed ligands expressed in the SAE-enriched
transcriptome at RPKM > 5. This observation is of
interest, as it suggests that much of the biology of the
SAE relates to interactions of the SAE as target (recep-
tors) or source (ligands) of external stimuli modulating
SAE function or vice versa.
Gene Families
One advantage of RNA-Seq compared to microarray is
that transcripts can be unequivocally mapped to a single
member of a gene family when sequence is similar but
not identical. Thus, RNA-Seq can be used to identify
and quantify highly homologous genes, something not
possible with hybridization-based microarrays [25]. To
quantify SAE expression of homologous gene families in
healthy nonsmokers, we identified all gene pairs with ≥
90% sequence identity and assessed expression level by
RNA-Seq in healthy nonsmokers. For example, in the
cluster on chromosome 19 containing CYP2A6,
CYP2A7 and CYP2A13 (Figure 5A), it was possible to
map the reads to the different genes and show that
expression of CYP2A13 (median RPKM = 17) >
CYP2A6 (4) > CYP2A7 (1). In the GSTA cluster on
chromosome 6 (Figure 5B), a clear assignment of reads
permitted the expression order of GSTA1 (249) >
GSTA2 (144) > GSTA3 (16) > GSTA5 (9). As another
example, in the metallothionein gene cluster on chro-
m o s o m e1 6( F i g u r e5 C ) ,i tw a se v i d e n tt h a te x p r e s s i o n
level for MT1E (33) > MT1lL (2) > MT1M (1). Among
the other highly expressed homologous gene families in
the SAE were the a and b tubulins, annexins, glu-
tathione S-transferase mu family, cytosolic phenol-pre-
ferring sulfotransferase family, a amylase, and NODAL
modulator (Table 6). In all cases, the RNA-Seq allows
the individual transcripts to be definitively distributed
among family members.
Effect of Smoking on the SAE Transcriptome
The preceding analyses of SAE-specific and ubiquitous
transcripts are based exclusively on the RNA-Seq data
from n = 5 nonsmokers. RNA-Seq data was also col-
lected for n = 6 healthy smokers, who had a mean
s m o k i n gh i s t o r yo f3 5p a c k - y r( r a n g eo f2 6t o4 5p a c k -
yr). Extensive transcription data based on the microarray
methods has shown that smoking makes a substantial
impact on gene expression in airway epithelium
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Page 8 of 31Table 2 Most Highly Expressed Genes Enriched in Differentiated Cell Types of the SAE of Healthy Nonsmokers
1
Differentiated cell type Gene
symbol
Gene title Expression level in SAE
(RPKM)
2
Ciliated TUBB2C tubulin, beta 2C 1161
ACTG1 actin, gamma 1 513
TUBA1A tubulin, alpha 1a 342
HSPA1A heat shock 70 kDa protein 1A 266
HSPA1B heat shock 70 kDa protein 1A///heat shock 70 kDa protein 1B 260
TEKT2 tektin 2 (testicular) 146
DYNLT1 dynein, light chain, Tctex-type 1 131
DNAI1 dynein, axonemal, intermediate chain 1 108
DNALI1 dynein, axonemal, light intermediate chain 1 108
DNAI2 dynein, axonemal, intermediate chain 2 105
SPAG6 sperm associated antigen 6 101
DYNLRB2 dynein, light chain, roadblock-type 2 100
CROCC ciliary rootlet coiled-coil, rootletin 84
PPP2R1A protein phosphatase 2, regulatory subunit A, alpha 73
DNAH9 dynein, axonemal, heavy chain 9 63
CCDC146 coiled-coil domain containing 146 60
RSPH4A radial spoke head 4 homolog A (Chlamydomonas) 59
CALM3 calmodulin 3 (phosphorylase kinase, delta) 56
TCTEX1D2 Tctex1 domain containing 2 50
IFT140 intraflagellar transport 140 homolog (Chlamydomonas) 49
Mucins and mucus
components
AGR2 anterior gradient homolog 2 166
TFF3 trefoil factor 3 (intestinal) 149
MUC1 mucin 1, cell surface associated 123
MUC5B mucin 5B, oligomeric mucus/gel-forming 118
MUC4 mucin 4, cell surface associated 93
MUC15 mucin 15, cell surface associated 28
MUC20 mucin 20, cell surface associated 27
MUC16 mucin 16, cell surface associated 20
MUC13 mucin 13, cell surface associated 15
MUCL1 mucin-like 1 3.90
TFF1 trefoil factor 1 2.09
PARM1 prostate androgen-regulated mucin-like protein 1 1.85
EMR2 egf-like module containing, mucin-like, hormone receptor-like 2 1.38
GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 0.81
MUC2 mucin 2, oligomeric mucus/gel-forming 0.60
MUC6 mucin 6, oligomeric mucus/gel-forming 0.58
MUC12 mucin 12, cell surface associated 0.46
Basal MALAT1 metastasis associated lung adenocarcinoma transcript 1 (non-protein
coding)
461
CST3 cystatin C 295
PFN1 profilin 1 224
ALDOA aldolase A, fructose-bisphosphate 183
SQSTM1 sequestosome 1 106
MT2A metallothionein 2A 91
ENO1 enolase 1, (alpha) 89
KRT7 keratin 7 83
MYL12A myosin, light chain 12A, regulatory, non-sarcomeric///myosin, light chain
12B, regulatory
70
FLNB filamin B, beta 69
BRI3 brain protein I3///hypothetical protein LOC644975 62
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Page 9 of 31[11-18,45,46]. Quantitative comparison by RNA-Seq of
SAE gene expression of healthy smokers vs healthy non-
smokers showed there was no gross effect of smoking
on the overall distribution of the SAE transcriptome in
nonsmokers and smokers (Figure 6A). However, there
were changes in expression of individual genes with
smoking, constituting 8 to 13% of the ubiquitous genes
and 9 to 14% of the SAE-enriched genes (Figure 6B). In
both categories, smoking responsiveness was slightly
more noticeable in genes with medium and high expres-
sion than in genes with low expression.
To assess the quantitative effects of smoking, a modi-
fied volcano plot was devised in which the absolute
change was plotted as a function of p value (Figure 6C,
D). The data show that, for both the ubiquitous and for
the SAE-enriched transcriptome, the number of genes
down-regulated by smoking was substantially higher
than that number of genes up-regulated by smoking.
This was particularly noticeable among the ubiquitous
genes.
Because of the extensive microarray data on the
response of airway epithelium to smoking, we sought to
validate the RNA-Seq data by comparing the response
to smoking as measured by the two different methods.
Micorarray data from a cohort of 12 healthy smokers
and 12 non-smokers were used to generate a list of 239
genes represented by 262 probesets that were smoking-
responsive (corrected p < 0.05, no fold change cutoff)
according to microarray. The fold-change by microarray
was plotted against the fold change by RNA-Seq with an
overall very strong correlation (r
2 = 0.89, Figure 7A;
Additional file 1, Table S5). There were no genes for
which the direction of regulation by smoking differed
between microarray and RNA-Seq method. Therefore,
RNA-Seq comprehensively captures the effect of smok-
ing as determined by microarray method, thereby vali-
dating both approaches. The ability of the microarray
method to capture the smoking-dependent gene expres-
sion detected by RNA-Seq was then assessed. RNA-Seq
method using n = 5 nonsmokers and n = 6 smokers
captured 611 smoking-dependent genes (uncorrected p
< 0.005, no fold change cut off). For these genes, the
impact of smoking as determined by microarray was
generally similar (Figure 7B, r
2 = 0.58; data in Additional
file 1, Table S6). While RNA-Seq faithfully captures the
effects of smoking as determined by microarray, the
microarray method is less discriminating in capturing
the smoking-dependent expression determined by RNA-
Seq, consistent with the higher sensitivity of the latter
method.
To assign function to smoking dependent genes, Gene
Ontology searches of the Biological Process term were
used to classify the expression of the smoking-sup-
pressed and smoking-repressed genes (Figure 8). This
analysis also showed that, in almost all categories, the
expression of more genes was suppressed than induced.
Of interest, a comparison of function in the ubiquitous
and SAE-enriched categories pointed to some contrasts
of potential significance. For example, among genes
involved in transport, there were more smoking-induced
SAE-enriched genes than ubiquitous genes and also a
higher proportion of smoking-inducible genes in the
Table 2 Most Highly Expressed Genes Enriched in Differentiated Cell Types of the SAE of Healthy Nonsmokers
1
(Continued)
PLEC1 plectin 60
EIF5A eukaryotic translation initiation factor 5A 60
GNB1 guanine nucleotide binding protein (G protein), beta polypeptide 1 57
KRT5 keratin 5 54
PSMA7 proteosome subunit alpha type 7 53
CTTN cortactin 52
JUP junction plakoglobin 51
MGST1 microsomal glutathione S-trasnferase 51
LMNA laminin A 49
Neuro- endocrine ENO2 enolase 2 (gamma, neuronal) 23
GRP gastrin-releasing peptide 0.82
UCHL1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 0.65
SCG2 secretogranin II 0.48
ASCL1 achaete-scute complex homolog 1 (Drosophila) 0.34
CHGA chromogranin A (parathyroid secretory protein 1) 0.32
1 List includes genes known to be enriched in expression in ciliated cells (Dvorak et al. 2010) [52], secretory cells (consisting of all mucins and mucin
components), basal cells (Hackett et al. 2011) [30], and neuroendocrine cells (Carolan et al. 2008) [31]. The small airway epithelium expression level was
determined and the top 20 highly expressed (or all genes expressed from mucin list and neuroendocrine list, i.e. above threshold of 0.125) were tabulated in
descending order of expression level.
2 Median for n = 5 nonsmokers.
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Page 10 of 31SAE-enriched group compared to ubiquitous category.
Similarly, among proteases and anti-proteases, there was
some smoking-inducibility in the SAE-enriched genes,
but none for ubiquitous genes.
In contrast to microarray data that suggests that cyto-
chrome P450 genes and oxidant-related genes are those
most highly induced by smoking [11-18,45,47], quantita-
tive RNA-Seq analysis demonstrated the largest up-regu-
lation of a gene by smoking was b-microseminoprotein
(MSMB) and chromosome 20 open reading frame 114
(C20orf114, Table 7; see Additional file 1, Figure S1 for
examples of this and other RNA-Seq-identified smok-
ing-related genes). The most smoking-repressed genes
were SCGB1A1 and SCGB3A1, which were also the two
most highly expressed SAE genes in nonsmokers. The
smoking-induced down-regulation of SCGB1A1 gene
expression was dramatic, with an absolute decrease in
median RPKM from 38,675 (13.1% of total mRNAs) to
17,244 (6.5% of mRNAs).
To detect novel smoking-dependent genes, we
exploited the ability of RNA-Seq to quantify expression
of genes with low expression. Among the novel smok-
ing-inducible and smoking-suppressed genes with low
level expression were the smoking-inducible genes that
had been previously identified by microarray (e.g.,
AKR1B10, CYP1B1) [11,47], but also newly identified
smoking-induced genes, such as the oxido-reductase
AKR1B15 and transcription factor TPRXL (Table 7).
Similarly, new smoking-repressed genes were identified,
including transcription factor PAX1 and AZU1, an
inflammatory mediator [48].
Based on the number of SAE-enriched, smoking-
dependent transport genes (Figure 7), we examined the
expression of ion transport genes with low overall
Table 3 Highly Expressed SAE-enriched Transcription Factors
1
Category Gene symbol Gene title Median expression level (RPKM)
Basic helix-loop
-helix
ATF6B activating transcription factor 6 beta 26.4
BHLHE40 basic helix-loop-helix family, member e40 16.2
RFX3 regulatory factor X, 3 (influences HLA class II expression) 15.6
HES6 hairy and enhancer of split 6 (Drosophila) 13.6
FOXC1 forkhead box C1 9.3
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 9.1
HEY1 hairy/enhancer-of-split related with YRPW motif 1 9.1
Zinc finger TRIM29 tripartite motif-containing 29 77.3
KLF5 kruppel-like factor 5 (intestinal) 42.0
RREB1 ras responsive element binding protein 1 7.2
KLF4 kruppel-like factor 4 (gut) 7.1
Helix-turn-helix FOXJ1 forkhead box J1 363.1
ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific) 170.1
FOXA1 forkhead box A1 62.6
EHF ets homologous factor 39.1
TBX1 T-box 1 19.7
SATB1 SATB homeobox 1 19.3
MYB v-myb myeloblastosis viral oncogene homolog (avian) 15.9
SIX2 SIX homeobox 2 13.9
NKX2-1 NK2 homeobox 1 11.6
PHTF1 putative homeodomain transcription factor 1 10.9
TEAD3 TEA domain family member 3 10.9
ETV6 ets variant 6 10.6
FOXA2 forkhead box A2 6.9
b-scaffold SOX2 SRY (sex determining region Y)-box 2 71.3
RUNX1 runt-related transcription factor 1 16.7
SOX4 SRY (sex determining region Y)-box 4 11.4
TFCP2 transcription factor CP2 10.7
SOX21 SRY (sex determining region Y)-box 21 9.0
NFATC1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 7.8
SOX9 SRY (sex determining region Y)-box 9 7.7
1 The top 30 DNA-binding transcription factors were identified in the highly expressed SAE-enriched list for n = 5 healthy nonsmokers. They were categorized by
transcription factor family and sorted in descending order of expression within each category.
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Page 11 of 31expression (Figure 8). The significance of this gene
g r o u pi se v i d e n ti nt h ef a c tt h a tp o l y m o r p h i s m si nt h e
cystic fibrosis transmembrane conductance regulator
(CFTR) gene, a chloride transporter, result in cystic
fibrosis, a lethal hereditary disorder with a dramatic pul-
monary phenotype [49]. CFTR expression levels were in
the range of 2 to 4 RPKM corresponding to an average
of ~2 to 4 mRNA molecules per cell, a similar value to
that estimated by polymerase chain reaction methodol-
ogy [50]. There was no difference in CFTR expression
level between nonsmokers and smokers (Figure 9A). In
contrast, there were smoking-inducible transporters
including the CFTR related ATP-binding cassette, sub-
family C, member 3 (ABCC3), L-type calcium channel,
voltage-dependent, gamma subunit 4 (CACNG4), and
cyclic nucleotide gated channel, beta 1 (CNGB1, Figure
9B-D). There were also significantly smoking-suppressed
ion transporters, including solute carrier family 13,
member 2 (sodium dependent dicarboxylate transporter,
SLC13A2) and potassium voltage-gated channel, Shaw-
related subfamily, member 4 (KCNC4) detected (Figure
9E, F).
Effect of Smoking on Alternative Splicing
Among the advantages of RNA-Seq is the ability to
easily quantify different isoforms of one gene generated
by alternate splicing. The frequencies of reads that span
o n eo rm o r es p l i c ej u n c t i o nw e r eu s e dt oa s s e s st h e
relative levels of different isoforms separately in smokers
and nonsmokers. Interestingly, comparison of the
Table 4 Highly Expressed SAE-enriched Transmembrane Receptors
1
Category Gene
symbol
Gene title Median expression level
(RPKM)
G protein coupled/7
transmembrane
CELSR1 cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog,
Drosophila)
63.0
C5AR1 complement component 5a receptor 1 27.6
GPR110 G protein-coupled receptor 110 21.7
GPRC5C G protein-coupled receptor, family C, group 5, member C 20.3
OXTR oxytocin receptor 19.3
LPAR3 lysophosphatidic acid receptor 3 17.6
FZD6 frizzled homolog 6 (Drosophila) 12.5
PTGER4 prostaglandin E receptor 4 (subtype EP4) 9.2
VIPR1 vasoactive intestinal peptide receptor 1 8.8
ADRB1 adrenergic, beta-1-, receptor 7.8
GPR116 G protein-coupled receptor 116 7.5
FZD8 frizzled homolog 8 (Drosophila) 7.1
ADRA2A adrenergic, alpha-2A-, receptor 6.8
PTGFR prostaglandin F receptor (FP) 6.6
Cyclase related NRP2 neuropilin 2 12.0
NPR2 natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide
receptor B)
10.7
CRCP CGRP receptor component 10.4
IgG like SCARA3 scavenger receptor class A, member 3 21.8
PTPRT protein tyrosine phosphatase, receptor type, T 13.0
IL1R1 interleukin 1 receptor, type I 6.5
Ion channel GABRP gamma-aminobutyric acid (GABA) A receptor, pi 15.7
Serine kinase TGFBR2 transforming growth factor, beta receptor II (70/80 kDa) 8.8
Tyrosine kinase DDR1 discoidin domain receptor tyrosine kinase 1 140.3
FGFR3 fibroblast growth factor receptor 3 19.9
IGF1R insulin-like growth factor 1 receptor 15.2
PTK7 PTK7 protein tyrosine kinase 7 14.5
FGFR2 fibroblast growth factor receptor 2 11.6
MET met proto-oncogene (hepatocyte growth factor receptor) 8.5
EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b)
oncogene homolog, avian)
7.2
Other SORL1 sortilin-related receptor, L(DLR class) A repeats-containing 7.7
1 The top 30 transmembrane receptors were identified in the highly expressed SAE-enriched list for n = 5 healthy nonsmokers. They were categorized by
structural family and sorted in descending order of expres-sion within each category.
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Page 12 of 31splicing events between nonsmokers and smokers to the
expected distribution revealed no divergence (Figure 10).
This was true for both the ubiquitous and SAE-enriched
genes, suggesting there are no major smoking-depen-
dent differences in splicing patterns.
Discussion
The small airway epithelium, the cell population lining
the bronchial tree ≥ 6 generations, plays a central role
in normal lung function and in the pathogenesis of
many lung disorders [7]. Among the most common
SAE-associated diseases are those caused by cigarette
smoking, including chronic obstructive pulmonary dis-
ease (COPD) and lung adenocarcinoma. The develop-
ment of massive parallel RNA sequencing (RNA-Seq)
technology permits quantitative assessment of poly(A)
+
mRNA levels to a high degree of sensitivity [19-24].
Compared to hybridization-based methodologies of tran-
scriptome analysis, RNA-Seq has low background, broad
dynamic range and high specificity [22]. Using this
a p p r o a c h ,w eh a v eb u i l tu p o nt h eb o d yo fm i c r o a r r a y -
generated data to provide quantitative characterization
of the transcriptome of the normal healthy human SAE
and characterize how it changes with smoking [11-18].
By comparing the SAE RNA-Seq data to that of other
tissues and organs, the present study grouped the SAE
transcriptome into 2 categories: (1) ubiquitous genes, i.
e., SAE genes shared with other organs and tissues, and
(2) SAE-enriched genes, i.e., those expressed by the
SAE, but not in the majority of other organs and tissues.
Using this classification, and based on the capacity of
RNA-Seq to provide quantification of mRNA, we further
characterized the effect of smoking on the SAE
transcriptome.
SAE-enriched Transcripts
Comparison of the expression profile of different tissues
by RNA-Seq and Serial Analysis of Gene Expression
Table 5 Highly Expressed SAE-enriched Signaling Ligands and Growth Factors
1
Gene symbol Gene title Median expression level (RPKM)
MDK midkine (neurite growth-promoting factor 2) 59.8
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 49.3
CX3CL1 chemokine (C-X3-C motif) ligand 1 32.9
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 31.8
FSTL1 follistatin-like 1 27.9
CXCL6 chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 18.6
FGF14 fibroblast growth factor 14 16.5
DLL1 delta-like 1 (Drosophila) 13.6
JAG2 jagged 2 11.9
IL8 interleukin 8 8.6
CCL15 C-C motif chemokine 15 7.8
PDGFA platelet-derived growth factor alpha polypeptide 6.1
TNFSF12 tumor necrosis factor (ligand) superfamily, member 12 5.9
CCL23 chemokine (C-C motif) ligand 23 5.3
NMB neuromedin B 4.9
CCL5 chemokine (C-C motif) ligand 5 4.9
NPFF neuropeptide FF-amide peptide precursor 4.6
FAS fas (TNF receptor superfamily, member 6) 3.6
WIF1 WNT inhibitory factor 1 3.6
CCL18 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) 3.5
LTB lymphotoxin beta (TNF superfamily, member 3) 3.0
LIF leukemia inhibitory factor (cholinergic differentiation factor) 2.9
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 2.7
PTCH1 patched homolog 1 (Drosophila) 2.6
WNT5A wingless-type MMTV integration site family, member 5A 2.1
CCL17 chemokine (C-C motif) ligand 17 1.7
NRTN neurturin 1.7
AREG amphiregulin 1.4
CCL4 chemokine (C-C motif) ligand 4 1.3
NTS neurotensin 1.2
1 The top 30 signaling ligands and growth factors were identified in the highly expressed SAE-enriched list for n = 5 healthy nonsmokers.
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Figure 5 Examples of RNA-Seq quantification of small airway epithelium (SAE) expression levels of genes within gene families of ≥
90% homology. To identify gene families expressed by the SAE, the % identity between gene pairs expressed by the healthy nonsmoker SAE
was determined using BLAST, where each gene was blasted against a database of all human RefSeq mRNA [26]. Gene families were defined as
genes for which the alignments yielded ≥ 90% identity and the alignment length was at least 50% of both sequences. A. CYP2A6, CYP2A7 and
CYP2A13; B. GSTA1, GSTA2, GSTA3 and GSTA5; and C. MT1E, MT1L and MT1M.
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Page 14 of 31Table 6 Different Expression Levels Among Members of Common Gene Families Expressed in the SAE
1
Category Gene name Gene symbol Median expression level (RPKM)
Cilia tubulin, alpha TUBA1A 341.7
TUBA1B 162.6
TUBA1C 120.5
tubulin, beta TUBB2A 38.7
TUBB2B 23.3
TUBB4 14.8
Annexin (signal
transduction)
annexin A2 ANXA2 362.1
ANXA2P2 292.3
ANXA2P1 42.6
ANXA2P3 26.1
Glutathione
S-transferase alpha
glutathione S-transferase alpha GSTA1 248.9
GSTA2 143.9
GSTA3 15.9
GSTA5 9.3
Glutathione
S-transferase mu
glutathione S-transferase mu GSTM2 35.9
GSTM1 20.8
GSTM4 8.8
Sulfotransferase -
phenol preferring
sulfotransferase family, cytosolic, 1A, phenol-preferring SULT1A1 25.7
SULT1A4 14.6
SULT1A3 10.3
SULT1A2 5.4
SLX1A-SULT1A3
SLX1B-SULT1A4
Amylase amylase, alpha AMY1A 43.4
AMY1B 18.6
AMY1C 15.1
AMY2B 13.8
AMY2A 7.3
Polarity/left right
signaling
NODAL modulator NOMO2 22.4
NOMO1 16.0
NOMO3 14.3
Metallothionein metallothionein MT1E 33.2
MT1L 2.4
MT1M 1.1
MT1JP
P450 cytochrome P450, family 2, subfamily A, polypeptides CYP2A13 17.2
CYP2A6 4.2
CYP2A7 1.4
Aldo-keto reductase aldo-keto reductase family 7 AKR7A2 34.1
AKR7A3 3.0
AKR7L 1.5
AKR7A2P1
Aldehyde
dehydrogenase
alcohol dehydrogenase ADH1C 52.2
ADH1B 4.3
ADH1A 2.6
Short chain
dehydrogenase
dehydrogenase/reductase DHRS9 68.4
Hackett et al. BMC Genomics 2012, 13:82
http://www.biomedcentral.com/1471-2164/13/82
Page 15 of 31Table 6 Different Expression Levels Among Members of Common Gene Families Expressed in the SAE
1 (Continued)
MUC20 27.5
VPS53 4.0
SMU1 3.9
FAM153B 0.4
LEP 0.0
1 List of gene families identified using BLAST with ≥ 90% identity and alignment lengths of at least 50% in both sequences. They were categorized by gene
family and sorted in descending order within each category by median expression level for n = 5 nonsmokers.
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Figure 6 Overall impact of smoking on small airway epithelium gene expression. Shown are comparisons of RNA-Seq assessment of
genes expressed in the small airway epithelium (SAE) in nonsmokers (n = 5) vs smokers (n = 6). A. Cumulative frequency of expression levels as
a function of increasing RPKM. The data is shown as cumulative frequency in 1/2 log10 bins starting at the lower limit (RPKM 0.125, log10 = -0.9)
for healthy nonsmokers (blue) and healthy smokers (red). On an overall basis assessing all genes, there is no difference in the nonsmokers vs
smokers. B. Comparison of expression of the subset of smoking-responsive vs non-responsive genes for the ubiquitous and SAE-enriched genes.
Each category is divided into low, medium and high expression groups using the same criteria as in Figures 2, 3, with smoking-responsive genes
defined as p < 0.05. Ordinate - number of genes; abscissa - smoking responsive (red) and smoking non-responsive (blue) for ubiquitous and
small airway epithelium (SAE)-enriched genes. Note that for both ubiquitous and SAE-enriched genes, only a small fraction, and approximately
the same proportion (8-14%; low, medium, high), are smoking-responsive. C, D. Modified volcano plot showing absolute change in expression
level (RPKM smoker - RPKM nonsmoker) vs -log p value for ubiquitous and SAE-enriched genes. C. Ubiquitous genes. D. SAE-enriched genes.
Note that for both ubiquitous and SAE-enriched genes, more genes are down-regulated by smoking than up-regulated.
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Figure 7 Comparison of smoking dependent genes observed by microarray and RNA-Seq. A. Microarray-determined smoking-responsive
genes. The data includes all significant genes (Benjamini Hochberg corrected p value < 0.05; Additional file 1, Table S6) with > 1.5-fold different
in mean expression level between n = 12 smokers and n = 12 nonsmokers, as determined by microarray. For each probeset the corresponding
genes was assessed by RNA-Seq for n = 5 nonsmokers an n = 6 smokers and fold-change by microarray is plotted against the fold-change by
RNA-Seq. B. RNA-Seq-determined smoking-responsive genes. The data includes the fold-change of all genes significantly impacted by smoking
(uncorrected p < 0.005, 1.5-fold-change cut off), as assessed by RNA-Seq for n = 5 nonsmokers an n = 6 smokers. n = 12 nonsmokers and n =
12 healthy smokers were assessed by microarray and the fold-change for RNA-Seq is plotted against the fold-change for the probeset with
largest change.
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Figure 8 Functional categorization of small airway epithelium (SAE) ubiquitous and SAE-enriched smoking-responsive genes.T h e
smoking-responsive genes (p < 0.05) of the ubiquitous and SAE-enriched groups were assigned function based on Gene Ontology classification
and searches of NCBI databases. The 9 functional categories chosen accounted for the largest fraction of the genes that could be assigned
functional categories. For each category, the genes were divided into smoking-induced and smoking-repressed and the log10 of absolute
change (RPKM smoker - RPKM nonsmoker) was plotted. Genes are divided by category and ordered within each category by decreasing change
in expression level. Red - down-regulated; blue - up-regulated. Note that for both ubiquitous and SAE-enriched genes, a higher fraction of genes
in most categories are down-regulated, and that most up-regulated genes are in the SAE-enriched subgroup.
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Page 18 of 31Table 7 Small Airway Epithelium Expressed Genes Most Affected by Smoking1
RNA-Seq Micorarray
Category Gene
symbol
Gene title Nonsmoker
median
Smoker
median
Absolute
difference
2
Fold-
change
3
Fold-
change
3
p
value
4
Largest absolute increase
Ubiquitous FTL ferritin, light polypeptide 371.1 843.4 472.2 2.3 1.6 0.1784
PRDX1 peroxiredoxin 1 187 398.6 211.6 2.1 1.6 0.1083
FTH1 ferritin, heavy polypeptide 1 349.2 551.5 202.3 1.6 1.8 0.0602
TUBB2C tubulin, beta 2C 1161.3 1331.9 170.5 1.1 1.1 0.8995
CLU clusterin 498 665.2 167.3 1.3 1.5 0.2157
NQO1 NAD(P)H dehydrogenase, quinone 1 38.3 198.7 160.4 5.2 4.8 <
0.0001
UBB ubiquitin B 615.1 711.1 96 1.2 -1.0 0.9760
GSN gelsolin 93.1 174.9 81.8 1.9 1.4 0.4772
TUBA1A tubulin, alpha 1a 341.7 423.2 81.5 1.2 1.1 0.7340
ALDOA aldolase A, fructose-bisphosphate 182.9 263.4 80.5 1.4 1.5 0.1670
SAE-
enriched
MSMB microseminoprotein, beta- 333.1 3112.7 2779.6 9.3 2.0 0.0820
C20orf114 chromosome 20 open reading frame 114 1484.3 4102.7 2618.5 2.8 1.1 0.6685
ALDH3A1 aldehyde dehydrogenase 3 family, member A1 226.9 2077.9 1851 9.2 9.8 <
0.0001
TFF3 trefoil factor 3 (intestinal) 149.4 697.9 548.5 4.7 2.8 0.1771
WFDC2 WAP four-disulfide core domain 2 840.3 1327 486.7 1.6 1.3 0.5735
TPPP3 tubulin polymerization-promoting protein family
member 3
1301.7 1604.9 303.2 1.2 -1.0 0.9493
TSPAN1 tetraspanin 1 663.9 960.2 296.3 1.4 1.1 0.8884
S100P S100 calcium binding protein P 79.6 291.2 211.5 3.7 1.8 0.4832
GSTA2 glutathione S-transferase alpha 2 143.9 337.5 193.6 2.3 Not in
U133
PLUNC palate, lung and nasal epithelium associated 5.4 186 180.6 34.5 1.6 0.8375
Largest absolute decrease
Ubiquitous CRIP1 cysteine-rich protein 1 (intestinal) 1014.1 587.7 -426.3 -1.7 -1.4 0.4842
RPLP1 ribosomal protein, large, P1 916.1 516 -400.1 -1.8 -1.2 0.3845
CAPS calcyphosine 2197.4 1994.7 -202.8 -1.1 -1.5 0.1733
PRDX5 peroxiredoxin 5 1022.4 823.3 -199.1 -1.2 -1.2 0.3653
RPS11 ribosomal protein S11 537.2 357.5 -179.7 -1.5 -1.3 0.3209
RPLP2 ribosomal protein, large, P2 347.5 181.2 -166.4 -1.9 -1.2 0.6557
RPL8 ribosomal protein L8 631.5 468.9 -162.6 -1.3 -1.2 0.5028
TPT1 tumor protein, translationally-controlled 1 655.2 500.7 -154.5 -1.3 -1.1 0.6701
S100A6 S100 calcium binding protein A6 758.3 617.2 -141 -1.2 -1.1 0.9250
CD81 CD81 molecule 248.3 120.5 -127.8 -2.1 -1.3 0.3499
SAE-
enriched
SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) 38675.4 17244 -21431.5 -2.2 -1.1 0.4670
SCGB3A1 secretoglobin, family 3A, member 1 7838.2 2947.3 -4890.8 -2.7 -1.3 0.1509
CD74 CD74 molecule, major histocompatibility
complex, class II invariant chain
947.2 723.7 -223.5 -1.3 -2.1 0.2881
C9orf24 chromosome 9 open reading frame 24 628.7 488 -140.7 -1.3 -1.3 0.2256
CYP4B1 cytochrome P450, family 4, subfamily B,
polypeptide 1
373.5 259.3 -114.2 -1.4 -1.6 0.1826
C20orf85 chromosome 20 open reading frame 85 738.1 625.3 -112.8 -1.2 -1.2 0.4756
KRT19 keratin 19 493.4 396.8 -96.6 -1.2 -1.1 0.7722
RPS18 ribosomal protein S18 285 207.8 -77.3 -1.4 -1.2 0.3731
ALDH3B1 aldehyde dehydrogenase 3 family, member B1 341.9 265.1 -76.7 -1.3 -1.5 0.3595
TMEM190 transmembrane protein 190 945.4 868.8 -76.6 -1.1 -1.2 0.5710
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Page 19 of 31(SAGE) allows the identification of ubiquitous and tissue
specific genes [24,51]. By comparing to the RNA-Seq
data obtained for other organs and tissues, we found
that among 15,877 genes expressed in the SAE, 52% of
genes are enriched in the SAE in a relatively selective
manner and 48% of genes are ubiquitous. Interestingly,
the SAE transcriptome includes more tissue-characteris-
tic RNAs than other epithelial (breast, kidney, colon)
and non-epithelial (heart, brain, skeletal muscle, adipose
tissue, lymph node) tissues, where ubiquitous genes con-
tribute to 65 to 85% of the transcriptome [24]. This may
reflect the high purity of the epithelial cells obtained by
bronchial brushing (i.e. they are not contaminated by
endothelium, connective tissue or inflammatory cells
and therefore do not appear to express genes that are
expressed by contaminating cell types). Notably, SAE
genes with low expression levels contributed to 36% of
the SAE-enriched and only 2% of ubiquitous genes, indi-
cating that molecular uniqueness of the SAE is deter-
mined to a considerable degree by the transcripts with a
low abundance. From the functional perspective, ubiqui-
tous SAE genes dominated in the categories related to
housekeeping biologic processes such as translation and
transcription, whereas SAE-enriched genes were preva-
lent in more specific categories such as immunity, signal
transduction, adhesion, and ion transport.
SAE Transcriptome Specialization
Specialized biological properties of a given organ or tis-
s u ea r ed e t e r m i n e db yau n i q u ep a t t e r no fg e n e s
Table 7 Small Airway Epithelium Expressed Genes Most Affected by Smoking1 (Continued)
Novel genes up-regulated by smoking
Ubiquitous AHRR aryl-hydrocarbon receptor repressor 0.1 1.3 1.2 20.8 3.7 0.0054
SAE-enriched AKR1B10 aldo-keto reductase family 1, member B10 (aldose
reductase)
0.3 28.5 28.2 94.8 56.6 <
0.0001
CABYR calcium binding tyrosine-(Y)-phosphorylation
regulated
1 12.5 11.6 12.7 9.4 <
0.0001
SPP1 secreted phosphoprotein 1 0.8 10.6 9.8 12.9 8.5 0.0021
CYP1B1 cytochrome P450, family 1, subfamily B,
polypeptide 1
0.2 9.2 9 43.3 55.0 <
0.0001
AKR1B15 aldo-keto reductase family 1, member B15 0.1 6.5 6.3 50 Not in
U133
B3GNT6 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 6 (core 3 synthase)
0.3 4.4 4.1 16 4.5 0.0525
NOS3 nitric oxide synthase 3 (endothelial cell) 0.6 4 3.4 6.5 “P” <
25%
TPRXL tetra-peptide repeat homeobox-like 0.3 3.2 2.9 10.2 3.8 0.0761
SFRP2 secreted frizzled-related protein 2 0.3 2.7 2.4 9.8 9.7 0.0071
FAM177B family with sequence similarity 177, member B 0.2 2.5 2.3 11 Not in
U133
Low level expressed genes suppressed by smoking
Ubiquitous PANK1 pantothenate kinase 1 1.4 0.7 -0.7 -2.1 -1.9 0.0391
SAE-
enriched
LYPD2 LY6/PLAUR domain containing 2 23.9 1.7 -22.3 -14.5 Not in
U133
LYNX1 Ly6/neurotoxin 1 8.6 2 -6.6 -4.3 -1.8 0.3058
AZU1 azurocidin 1 6.1 1.9 -4.3 -3.3 -2.1 0.2405
ITM2A integral membrane protein 2A 5.2 1.3 -4 -4.2 -2.6 0.0071
ITM2A integral membrane protein 2A 5.2 1.3 -4 -4.2 -2.6 0.0071
SAA4 serum amyloid A4, constitutive 4.8 1.4 -3.4 -3.4 -3.4 0.0147
GAL3ST2 galactose-3-O-sulfotransferase 2 4.7 1.6 -3.1 -2.9 “P” <
25%
NEU4 sialidase 4 3.7 0.7 -3 -5.4 -1.2 0.6483
PAX1 paired box 1 3.6 1 -2.6 -3.5 -1.9 0.3312
ERP27 endoplasmic reticulum protein 27 2.4 0.5 -2 -5.2 -4.4 0.0016
1 The top 20 genes were identified in four categories of genes most affected by smoking; largest absolute increase, largest absolute decrease, novel genes up-
regulated by smoking and low level expressed genes suppressed by smoking. They were sorted in descending order of absolute difference in expression within
each category and identified as being from the ubiquitous or small airway epithelium-enriched groups.
2 Absolute difference = smoker median - nonsmoker median
3 Fold change = mean in smokers/mean in non smokers
4 Benjamini-Hochberg corrected p value. Where the gene is not represented on the microarray or the Affymetrix Present call “P” is less than 25% of subjects, it is
so indicated.
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Figure 9 RNA-Seq quantification of examples of smoking-dependent changes in expression of ion channel-related genes expressed in
the small airway epithelium. Smoking responsiveness of selected ion channels. A. CFTR - unchanged; B-D. Up-regulated. B. ABCC3; C.
CACNG4; and D. CNGB1. E-F. Down-regulated. E. SLC13A2; and F. KCNC4. In all panels, each data point represents one individual.
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Page 21 of 31expressed in distinct cell populations typical for each tis-
sue. The human SAE is composed of various cell types,
including ciliated, secretory (mostly Clara cells but also
surface epithelium mucus-producing cells), basal, undif-
ferentiated columnar, and rare neuroendocrine cells
[1,2,13,31,52]. Although most of the SAE-enriched genes
are represented by low expressed transcripts, the top 30
highly expressed SAE-enriched genes accounted for
about 20% of the total SAE mRNA, suggesting that a
limited number of genes may dictate the specific pattern
of biological processes dominating in the SAE under
steady-state conditions. Detailed analysis of the most
highly expressed SAE-enriched genes revealed a unique
pattern of epithelial differentiation and molecular
functions.
Secretory differentiation
Genes related to secretory epithelial differentiation
dominated the most highly expressed SAE-enriched
genes. Of the total SAE transcripts identified, 13%
mapped to the secretoglobin SCGB1A1. The high level
of expression of SCGB1A1 is expected in the SAE,
where Clara cells are enriched and play an important
role in the pulmonary host defense [27-29]. SCGB1A1,
is involved in regulation of critical processes in the dis-
tal airways such as protection against oxidative stress,
maintenance of the normal airway lining fluid homeos-
tasis, regulation of inflammation and airway reactivity
during respiratory infection, and control of macrophage
activation in the lung [53-57]. Another secretoglobin,
SCGB3A1, originally called HIN-1, was the second-high-
est expressed SAE-enriched gene. Previous studies have
identified the lungs as major site of SCGB3A1 in
humans [58]. Expression of SCGB3A1 is induced during
epithelial differentiation and restricted to terminally dif-
ferentiated airway epithelial cells and down-regulated in
cancer [58,59]. There is evidence that SCGB3A1 is also
produced by Clara cells [60] and exerts growth-inhibi-
tory activities [61]. Consistent with its putative tumor-
suppressor function, SCGB3A1, is aberrantly methylated
in various types of cancer, including lung carcinomas
[62]. Based on previous observations, the quantitative
data in the present study suggests that SCGB3A1 could
be a major steady-state tumor-suppressor gene in the
human SAE.
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Figure 10 Quantile-quantile plot of significance of difference in splice junction usage between smokers and nonsmokers. Normalized
reads supporting splicing in the smokers and nonsmoker samples were compared. The data shows that smoking caused no significant
difference in the splicing for either the ubiquitously expressed genes (blue) or SAE-enriched genes (green).
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Page 22 of 31High expression of Clara cell-associated secretoglobin
genes in the SAE was accompanied with enrichment of
transcription factors forkhead box A1 (FOXA1), NK2
homeobox 1 (NKX2-1), FOXA2, and CCAAT/enhancer
binding protein, alpha (C/EBPa), transcription factors
that constitute a major regulatory network for the devel-
opment and maintenance of SAE and Clara cell differen-
tiation [43,63-65]. NKX2-1 interacts with FOXA1 [34],
FOXA1 and FOXA2 complement each other [35], and
both NKX2-1 and FOXA2 are thought to act upstream
of C/EBPa in lung epithelial differentiation [65,66]. A
number of secretory genes, not previously described for
the human SAE, were identified by RNA-Seq as highly
abundant SAE-enriched genes, including tetraspanin-1
(TSPAN1), a protein involved in secretory pathways in
glandular cells [67], cytochrome CYP4B1, a CYP family
member localized within the secretory granules of the
respiratory mucosa [68], and microseminoprotein-beta
(MSMB), an androgen-responsive secretory protein reg-
ulating cell growth and apoptosis [69].
Mucosal host defense
Secretory leukocyte peptidase inhibitor (SLPI) and
polymeric immunoglobulin receptor (PIGR), two key
components of the mucosal defense system, were
among the most highly expressed SAE-enriched genes.
SLPI has multiple contributions to pulmonary defense,
including its ability to neutralize neutrophil elastase,
one of the major mediators of lung derangement asso-
ciated with inflammatory diseases, direct antimicrobial
and anti-inflammatory activities, and augmentation of
anti-oxidant resistance by increasing glutathione levels
in the respiratory surface fluid [70-73]. PIGR is essen-
tial for the transepithelial basal-to-apical transport of
the polymeric immunoglobulin IgA to the epithelial
surface, where it functions to sample and neutralize
luminal pathogens [74]. Lipocalin 2 (LCN2), a sidero-
phore-binding antimicrobial protein secreted by pul-
monary epithelial cells [75], and the whey acid protein
four-disulfide core domain 2 (WFDC2), a SLPI-related
gene with potential innate immune functions [76],
were also among the most abundant genes enriched in
the SAE. Among the most highly expressed genes in
the SAE was ELF3, a helix-loop-helix transcription fac-
tor expressed in diverse epithelial tissues implicated in
the regulation of inflammatory responses [39]. In the
context that the airway epithelium is at the interface of
the environment (the apical surface) and potential
inflammatory/immune mediators (the basolateral sur-
face), the host defense genes identified in the present
study as the most abundant SAE genes may play a cen-
tral role in both mediating and controlling the
responses of the airway to environmental xenobiotics
and pathogens.
Anti-oxidant protection
The ability to resist deleterious effects of the oxidative
stress is critical for the SAE, continuously interacting
with oxidants present in the inhaled air. Apart from the
secretory genes with anti-oxidant functions such as
SCGB1A1 and SLPI, a number of other genes directly
related to the protection from oxidative stress, including
glutathione S-transferases pi 1 and alpha 1, and glu-
tathione peroxidase 1 (GPX1), were identified as highly
expressed SAE-enriched genes. One of these compo-
nents, GPX1, also known as Clara cell-specific protein
CC26, is selectively expressed by Clara cells [55], sug-
gesting that high abundance of both secretory and oxi-
dative stress-related features in the SAE might reflect a
secretory cell origin of at least some of the anti-oxidant
mechanisms in the human SAE.
Mucociliary differentiation
Consistent with the abundance of ciliated cells in the
human SAE, transcription factor FOXJ1, the major regu-
lator of ciliogenesis and ciliated cell differentiation in
the airway epithelium [41,42], was among the top 20
SAE-enriched genes and the most highly expressed tran-
scription factor. Other cilia-related genes enriched in the
SAE were tektin-1 and -2, structural determinants of the
basal bodies of cilia [77], cilia apical structure protein
sentan [78], dynein chains DNAI1, DNALI1, DNAI2
and sperm associated antigen SPAG6, the classic com-
ponents of motile cilia [79]. In addition to these well-
known genes, RNA-Seq analysis revealed that several
recently discovered cilia-related genes were highly
enriched in the human SAE, including the member of
the membrane-spanning 4-domain family MS4A8B,
which has high sequence homology to cilia-associated
gene L985P [80].
Surprisingly, a considerable number of mucus-related
genes, such as trefoil factor 3 [81], mucin 1 and mucin
5B [82,83], were highly expressed in the SAE transcrip-
tome along with AGR2, a secretory factor related to
goblet cell differentiation [84,85]. Of note, as compared
to the large airways, where secreted polymeric mucins
are abundant [86], the SAE transcriptome was enriched
in membrane-tethered mucins such as MUC1, MUC4,
MUC15, MUC20, MUC16, and MUC13, which have
various signaling functions [87].
Stem/progenitor cell features
Although Clara cells are considered to be stem/progeni-
tor cells of the mouse bronchiolar epithelium [8,88], the
identity of stem/progenitor cell population of the SAE
in humans is unknown. Several genes related to stem/
progenitor cells were identified in the present study as
SAE-enriched genes, including aquaporin-3, a marker of
basal cell and suprabasal cell populations with progeni-
tor cell function described for the human
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Page 23 of 31tracheobronchial epithelium [89] and aldehyde dehydro-
genase ALDH1, a marker of normal and malignant stem
cells in various tissues [90,91]. It is notable that among
the top 5 highly-expressed SAE-enriched transcription
factors were ELF3, which promotes epithelial morpho-
genesis [92], and embryonic stem cell-related gene
SOX2, recently shown to be important for the progeni-
tor cell function of the airway basal cells and Clara cells
and induction of the airway epithelial cell phenotype in
mice [36-38]. Due to its high sensitivity, RNA-Seq analy-
sis also identified markers of the putative stem/progeni-
tor cells previously found in the airway epithelium with
relatively low frequency, such as keratin 14, a marker of
a basal cell subpopulation [93], and surfactant protein
C, a gene ascribed to a unique population of bronchoal-
veolar stem cells in mice [88]. Together, the RNA-Seq
data of the present study demonstrates SAE expression
of multiple pathways potentially relevant for the mainte-
nance of hu-man SAE via local stem/progenitor cell
activity.
Transmembrane receptors, signaling ligands and growth
factors
The most highly expressed transmembrane receptor in
SAE of nonsmokers was DDR1 (discoidin domain recep-
tor 1), a receptor tyrosine kinase [44]. Expression of the
DDR1 protein is located on the basolateral surface of
human bronchial epithelium, where it interacts with
type IV collagen with consequent activation of its tyro-
sine kinase activity. The second most abundant SAE-
enriched receptor was CELSR1 (cadherin, EGF LAG
seven-pass G-type receptor 1), a G protein coupled
receptor known to be critical for branching morphogen-
esis in mouse lung [94]. The most highly expressed
SAE-enriched ligand was midkine (MDK), which has a
role in lung morphogenesis and is believed to be essen-
tial for vascular maintenance in the adult lung [95]. In
mouse, midkine expression is controlled by Nkx2-1 [96]
which, as mentioned above, is also highly expressed in
the human SAE. Among the highly expressed ligands,
there was a clear prevalence of chemokines such as
MDK, CXCL1 and CX3CL1. Consistent with this obser-
vation, expression of diverse cytokines by airway epithe-
lium and cell lines derived from airway epithelium is
well established and epithelial derived chemokines are
recognized to play an important role in attracting
immune and inflammatory cells [97,98].
The RNA-Seq data also pointed to potentially novel
aspects of cell signaling in epithelial biology. For exam-
ple, the oxytocin receptor (OXTR) was expressed at
high levels in all subjects who were male. This was initi-
ally surprising due to roles of oxytocin in childbirth, lac-
tation and brain biology [99] but, relevant to the airway
epithelium, a role for oxytocin in autocrine signaling in
small cell lung cancer has been described [100].
Gene Family Members
RNA-Seq offers the potential advantage of distinguishing
expression levels among different members of closely
related gene families with potentially different functions,
whereas cross hybridization among probes often makes
this a challenge using microarrays [25]. For example, the
RNA-Seq analysis permitted quantification of the
expression levels of 3 highly different homologous mem-
bers of the cytochrome P450 family 2, subfamily A,
CYP2A6, CYP2A7 and CYP2A13. RNA-Seq allowed the
transcripts to be unambiguously attributed primarily to
CYP2A13 which is responsible for metabolism of the
cigarette smoke specific carcinogen 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone [101]. On the other
hand, the family member CYP2A6 has different sub-
strate specificity dictated by critical amino acid differ-
ences between these otherwise closely related proteins
[102]. The significance of these differences are under-
scored by the variant CYP2A13*2, which is associated
with decreased incidences of lung adenocarcinoma in
smokers [103].
SAE Transcriptome Response to Smoking
Extensive microarray studies have identified a dramatic
effect of smoking on the gene expression profile of
human airway epithelium [11-18]. By using RPKM
quantification as a measure of smoking-dependent
changes in SAE transcript levels, the present study
expands the insights into the airway epithelial response
to smoking. The quantitative RNA-Seq analysis revealed
that smoking suppressed the expression level of a
greater number of genes than it induced. Interestingly,
among the up-regulated genes, smoking has a larger
effect on SAE-enriched genes rather than the ubiquitous
genes. From the functional perspective, the SAE-
enriched smoking-up-regulated genes were related to
transcription, signal transduction, protease/antiprotease
homeostasis, and immunity.
The top 2 SAE-enriched genes, the Clara cell asso-
ciated genes SCGB1A1 and SCGB3A1, were both down-
regulated by smoking with a large magnitude of change
in expression levels. Smoking and especially COPD have
been associated with the loss of Clara cells and the
levels of SCGB1A1 in both induced sputum and serum
are lower in smokers with COPD as compared to both
nonsmokers and healthy smokers [104-107]. It is possi-
ble that down-regulation of Clara cell secretoglobins,
with their anti-oxidant, anti-inflammatory and tumor-
suppressor activities [60,108,109], is a critical compo-
nent of smoking-related development of COPD. The
decreased number of SCGB1A1-expressing Clara cells in
smokers is generally accompanied by an increased fre-
quency of mucin-secreting cells [29]. Indeed, a subset of
highly expressed SAE-enriched genes, such as
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both associated with mucin-producing secretory cell
phenotype [110,111], were among the smoking-induced
genes with the highest amplitude of up-regulation.
Other genes related to a secretory phenotype such as
WFDC2, TSPAN1, TFF3, S100P, and short PLUNC,
were also induced by smoking; each of these genes has
been associated with epithelial carcinogenesis
[67,112-115]. Thus, a broad induction of a mucin-pro-
ducing cell secretory program, characteristic of epithelial
malignancies, may represent an early molecular pheno-
type relevant to smoking-induced carcinogenesis in the
distal airways.
Other smoking-induced changes among the highly
expressed SAE-enriched genes included up-regulation of
oxidative stress-related genes ALDH3A1 and GSTA2,
also associated with cancer development [116,117], and
down-regulation of genes associated with epithelial dif-
ferentiation such as CD74, C9orf24 (also known as
ciliated bronchial epithelium 1), and luminal cell-asso-
ciated keratin 19[118,119]. Some of these changes have
not been previously detected by microarrays, likely due
to microarray saturation of signal with high levels of
expression and/or higher sensitivity of the RNA-Seq
methodology to gene expression changes with relatively
low overall fold-difference between the groups.
The ability of RNA-Seq to assess genes with low
steady-state expression was utilized in the present study
to characterize the effect of smoking on the expression
of low abundance SAE genes. Although some of
changes, such as up-regulation of oxidative stress-
responsive genes AKR1B10, CABYR, and CYP1B1 have
been previously reported [11,45-47], RNA-Seq quantifi-
cation revealed a number of novel smoking-responsive
genes, including smoking-induced NOS3, a gene encod-
ing nitric oxide isoform usually expressed by endothelial
cells but induced in the airway epithelium in association
with squamous differentiation [120], and smoking-sup-
pressed Ly6/neurotoxin 1 (LYNX1), an allosteric modu-
lator of nicotinic acetylcholine receptors [121].
Functional classification of the low level, smoking-
related genes also identified the class of ion transport
genes as being modulated by smoking. One example
was CNGB1, a smoking-induced gene that encodes a
cyclic nucleotide gated channel that was first identified
for its role in light activated cellular polarization in ret-
inal photoreceptor cells [122] and linked to olfactory
receptor function [123]. The discovery that airway
ciliated cells have olfactory receptors that operate by the
same signal transduction pathways as visual rhodopsin
[124] suggests a role for CNGB1 in airway epithelial
function. Also notable among smoking-dependent genes
were a series of ion channels whose overall low expres-
sion level in the SAE may reflect expression
predominantly in neuroendocrine cells which constitute
< 0.01% of total airway epithelium. For example,
CACNG4, the gamma subunit of a voltage gated cal-
cium channel, is a smoking-induced gene. Previous
reports suggest that this gamma subunit is expressed
primarily in brain [125] but expression of voltage gated
calcium channels in neuroendocrine cells and neuroen-
docrine-derived tumors has been demonstrated [126].
Splicing
The mRNA sequence reads across exon junctions per-
mit quantitative assessment of the splicing pattern for
all genes. By comparing splice events for smokers and
n o n s m o k e r s ,w ew e r ea b l et od e m o n s t r a t et h e r ea r en o
overall smoking-dependent changes in the patterns of
splicing for either ubiquitous or SAE-enriched genes.
This was surprising, since there are known to be sub-
stantial genome wide differences in splicing between
normal airway epithelium and lung cancer [127,128],
suggesting those splicing-related changes are late events
and are not represented in non-transformed airway
epithelial cells.
Conclusions
RNA-Seq method provides wide dynamic range and low
noise. Application of RNA-Seq to SAE allowed the
unequivocal identification of highly expressed ubiquitous
and SAE-enriched genes. Functional assignment of
highly expressed genes showed Clara cell specific genes
were most abundantly expressed. But genes characteris-
tic of minor cell types such as neuroendocrine cells
were also evident. Comparison of the transcriptome of
nonsmokers to that of healthy smokers allowed the
response of SAE to cigarette smoke to be quantified and
novel smoking-responsive genes to be identified.
Methods
Study Population
Following approval by the Weill Cornell Medical College
Institutional Review Board, healthy nonsmokers and
healthy smokers, who responded to local advertisements
regarding a research study to assess lung health, were
assessed in the Weill Cornell National Institutes of
Health Clinical and Translational Sciences Center and
Department of Genetic Medicine Clinical Research
Facility. Prior to study enrollment, each individual pro-
vided written informed consent. The study population
included healthy nonsmokers (n = 5) and healthy smo-
kers (n = 6), phenotyped by a standardized screening
assessment consisting of a history, physical examination,
complete blood count, coagulation profile, liver function
tests, urine studies, chest X-ray, EKG, and lung function
tests (see Additional Data Methods for inclusion/exclu-
sion criteria; Additional file 1, Table S1 for detailed
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to verify the self-reported smoking status of smokers.
For comparison between RNA-Seq and microarray data,
27 healthy nonsmokers from a previous study were
assessed [129] (see Additional file 1, Table S1 for demo-
graphic details).
Collection of SAE
Fiberoptic bronchoscopy was used to sample SAE cells
as previously described [13]. After routine anesthesia, a
2 mm disposable brush (Wiltek Medical, Winston-
Salem, NC) was inserted into the working channel of
the bronchoscope and advanced to the airways distal to
the orifice of the desired lobar bronchus. Small airway
epithelial samples were obtained by lightly wedging the
brush 7 to 10 cm distal to the 3
rd generation bronchial
airway (i.e., the 10
th to 12
th order bronchi), and sliding
the brush back and forth on the epithelium 10 to 20
times in 8 to 10 sites. For each brush, after withdrawing
from the bronchoscope, the cells were dislodged from
the brush by flicking the brush tip in 5 ml of ice-cold
Bronchial Epithelium Basal Medium (BEBM, Lonza,
Basel, Switzerland). A 1 ml aliquot of all airway epithe-
lial samples was used to quantify the percentage of
epithelial and inflammatory cells and the proportions of
basal, ciliated, secretory and undifferentiated columnar
cells by centrifuging 2 × 10
4 cells per slide (Cytospin 11,
Shandon Instruments, Pittsburgh, PA) and using Diff-
quik staining reagents (Dade Behring, Newark, NJ); a
portion of this aliquot was also used to quantify of the
number of cells recovered from airway brushings using
a hemocytometer. The remaining 4 ml of sample was
im-mediately processed for RNA extraction.
RNA Extraction and Sample Preparation
The freshly acquired small airway epithelial samples
were treated with TRIzol (Invitrogen Carlsbad, CA) to
extract total RNA, and residual DNA was removed by
RNeasy MinElute RNA purification kit (Qiagen, Valen-
cia, CA), resulting in a yield of between 2 and 4 :g RNA
per 10
6 cells. To assess the integrity of the RNA, an ali-
quot of each sample of RNA was analyzed with the Agi-
lent Bioanalyzer (Santa Clar a ,C A ) ,a n dt h eN a n o D r o p
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE) was used to determine the RNA con-
centration. Samples were then stored in RNAsecure
(Ambion, Austin, TX) until further analysis. Using the
reagents of the mRNA Sample Prep Kit and in accor-
dance with the RNA sequencing protocol provided by
Illumina, poly(A)
+ mRNA was selected out from the
total RNA samples using Sera-mag magnetic oligo(dT)
beads. An RNA fragmentation kit (Ambion, Austin, TX)
was used to fragment the mRNA, followed by first- and
second-strand cDNA synthesis using random hexamer
primers. An “end repair” reaction to blunt the ends of
all fragments was then performed with Klenow polymer-
ase and T4 DNA polymerase, and 3’-t o5 ’ exo-nuclease
w a su s e dt oc r e a t ea3 ’ adenine overhanging tail, facili-
tating the ligation of the amplification adapters. Ligation
products were then separated on a 2% tris-acetate-
EDTA-agarose gel for size selection, followed by purifi-
cation with a gel extraction kit. The purified ligation
products were then PCR amplified with complementary
primers and the resultant cDNA was purified with QIA-
quick PCR kit (Qiagen), and the concentration was mea-
sured by the NanoDrop spectrophotometer. Samples
were then loaded onto Illumina flow cells for single end,
43 nucleotide, sequencing reactions.
Data Filtering, Read Mapping and Quantification of Gene
Expression
Images acquired by the Illumina Genome Analyzer 2
were analyzed by Firecrest and bases called by Bustard
(both part of Illumina RTA pipeline version 1.6). All
lanes of data were required to show low overall error
rate (< 1.5%), low inter-base phasing (< 1.0), and all
reads passed the Illumina GA quality filters (PF = Y).
Resultant reads were aligned to the reference genome
build UCSC hg19 using Bowtie v 0.12 [130]. The Bowtie
default parameters used were those in which the first
seed alignment of size > 28 nt, allowing up to 2 mis-
matches, is chosen at random, and is used if it yields an
alignment quality sum of > 70 with a maximum of 125
backtraces. Thus, multiple alignments are not specifi-
cally assessed nor scored. The data was then processed
with Python scripts to assign aligned reads to the coor-
dinates of exons and genes. Mean read density values
for exons, introns, and intergenic regions were com-
puted in units of reads per kilobase of exon/intron/
intergenic per million mapped reads [23]. Reads were
mapped to the annotated transcribed strand of the gen-
ome, because the protocol for sequencing used in the
current study was not strand specific. Reads per kilobase
of exon per million mapped reads (RPKM) are indicative
of actual mRNA concentration when samples have rela-
tively uniform sequencing coverage across the entire
gene model [23].
To determine the minimum detectable level of expres-
sion, a false discovery rate (FDR) and false negative rate
(FNR) was estimated by comparing the expression levels
of known exons to intergenic regions (Figure 1). This
was done in accordance with the method described by
Ramsköld et al. [24]. The distribution of exon expres-
sion levels was compared to the expression levels of
intergenic regions based on the criteria: (1) no anno-
tated genes according to the NCBI Reference Sequence
(RefSeq; http://www.ncbi.nlm.nih.gov/RefSeq/) and
Ensembl http://www.ensembl.org databases; and (2) no
Hackett et al. BMC Genomics 2012, 13:82
http://www.biomedcentral.com/1471-2164/13/82
Page 26 of 31known expressed sequence tags in the GenBank
sequence database http://www.ncbi.nlm.nih.gov/genbank.
In order to avoid a bias due to changes in the size dis-
tribution of intergenic regions and exons, the intergenic
regions were chosen at random to have the same size
distribution of the expressed exons. The FDR was calcu-
lated for different expression levels as the normalized
ratio of number of intergenic regions to number of
exons at each expression level. The FNR for different
expression levels was estimated from the cumulative
ratio of the true positive rate (as estimated from the
product of number of expressed exons and the FDR)
and the total fraction of expressed exons. Based on this
analysis, the optimal expression value as defined by the
intersection of the FDR and FNR in all non-smoker
samples was 0.125 RPKM.
All sequence read data have been submitted to the
S h o r tR e a dA r c h i v e( S R A )s e c t i o no ft h eN C B IS R A
database (SRA accession #SRP005411); and U133 data
submitted to GEO (GSE27681).
Data Analysis
Ac u to f fv a l u eo fR P K M0 . 1 2 5w a se s t a b l i s h e d ,b e l o w
which expression was considered as noise (Figure 1).
Genes for which the median expression in nonsmokers
was > 0.125 RPKM were scored as expressed. Genes
expressed by the small airway epithelium (SAE) were
categorized as “ubiquitous” and “SAE-enriched” as fol-
lows. Ubiquitous genes were defined as described by
Ramsköld et al. [24] based on expression in 11 of 12 tis-
sues surveyed. The SAE expressed genes were grouped
as “ubiquitous” if also expressed in at least 11 of 12
other tissues or “SAE-enriched” (if not in the “ubiqui-
tous” list) [24]. Based on the median expression level in
nonsmokers, expressed genes were further divided into
“low” (RPKM 0.125 to 1), “medium” (RPKM between 1
and 10) and “high” expression genes (RPKM > 10).
The abundance of the transcripts from individual
g e n e si nt h et o t a lm R N Ap o o li nd i f f e r e n tt i s s u e sw a s
assessed by building a frequency distribution. For our
SAE data and for published RNA-Seq data from various
tissue [24], all genes were ranked by transcript abun-
dance and then the fraction of total mRNA contributed
by gene #1, genes #2-10, genes #11-100, genes #101-
1000 and # > 1000 was determined. This gives a fre-
quency distribution that could be compared among tis-
sues with assessment by Fisher’s exact test.
To compare the RNA-Seq data to that of microarrays,
Human Genome U133 Plus 2.0 microarray data (Affy-
metrix, Santa Clara, CA) from 27 healthy, African-
American nonsmokers was used ([129]; Additional file
1, Table S1). The microarray CEL files were analyzed by
Affymetrix Suite software and the “P” calls for each pro-
beset were totaled for all subjects. The gene list from
RNA-Seq was systematically reviewed in comparison to
the microarray data. Where there was a corresponding
probeset on the microarray data, the percentage of sub-
jects with “P” call was determined. When there was > 1
probeset corresponding to a single named gene, the pro-
beset with the highest percentage P call was used.
To further characterize the healthy SAE transcrip-
tome, the data from the healthy nonsmokers were
assessed for: (1) the overall most highly expressed genes;
(2) the most highly expressed genes of differentiated cell
types (ciliated, secretory, basal and neuroendocrine
cells), using lists of genes characteristic of these differen-
tiated cell types (Additional file 1, Table S4) [30,31,52];
(3) genes coding for transcription factors; (4) genes cod-
ing for transmembrane receptors; and (5) genes coding
for signaling ligands and growth factors. In all cases, the
most highly expressed was based on the median for all
nonsmokers. Gene families expressed by the SAE of
healthy nonsmokers were identified using Basic Local
Alignment Search Tool (BLAST; http://www.ncbi.nlm.
nih.gov/BLAST/). All RefSeq genes expressed by non-
smokers were aligned against a database of all human
RefSeq mRNA [26]. Gene families were defined as
groups of genes for which the alignments yielded ≥ 90%
identity and the alignment length was at least 50% of
both the query and matched sequences. Changes in
gene expression of the family members were assessed as
described above.
Smoking responsive genes were assigned on the basis
of comparing RPKM level in 5 nonsmokers to that in 6
smokers by t-test with no correction for multiple com-
parisons. All genes with a p value of < 0.05 were
deemed to be smoking-dependent regardless of any cut
off in absolute change or fold-change (smoker/nonsmo-
ker expression ratio).
The effect of smoking on alternative splicing was esti-
mated by comparing normalized splice junction usage.
To accomplish this, all reads that failed to align to the
reference genome were aligned (using Bowtie) to a data-
base of all RefSeq annotated exon-exon boundaries gen-
erated such that each junction required reads to overlap
each exon by at least 3 nucleotides. By normalizing the
number of reads at each junction by the length of each
junction in kilobases, number of reads in the sample in
millions of reads and the expression level of neighboring
exons, it was possible to compare junction usage even
in genes with different expression levels. To re-duce the
false positive rate, filteringi n c l u d e de x c l u s i o no fa l l
junctions with expression levels (RPKM) below 0.125, all
junctions with less than 2 spliced reads in both the smo-
ker and non-smoker samples, as well as any genes where
the standard error in RPKM across all samples was
greater than 0.5. A t-test was used to estimate the sig-
nificance of the difference in splice junction usage of the
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The data were analyzed using multiple test corrections
with evaluation by Q-Q plot.
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